Latest News and Press Releases

LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory...

LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1...

FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON, July 10, 2022 (GLOBE NEWSWIRE) -- Freeline...

LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...

LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from...

Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...

LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on April 29, 2022, the Company granted five newly hired...

LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...

LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that Paul M. Schneider has been appointed Chief Financial...

LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on February 28, 2022, the Company granted three newly...